Wuxi Runmin Pharmaceutical Technology

Wuxi Runmin Pharmaceutical Technology is a Chinese biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group. The company is primarily recognized for its role in developing Xiannuoxin (simnotrelvir/ritonavir), an oral small-molecule antiviral for COVID-19. Xiannuoxin targets the 3C-like protease (3CLpro) and was the first domestically developed treatment of its kind to receive marketing authorization in China. Wuxi Runmin works in close collaboration with the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology to advance its infectious disease pipeline. As a specialized entity within the Simcere ecosystem, it focuses on the rapid clinical development and commercialization of high-need innovative medicines. The company's operations are centered in Wuxi, China, where it leverages regional biotech infrastructure to support its R&D initiatives.